Veracyte VCYT United States — Total Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Veracyte in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Veracyte’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about Veracyte's united states — total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Veracyte's united states — total revenue?
- Veracyte (VCYT) reported united states — total revenue of $124.15M in Q4 2025.
- How has Veracyte's united states — total revenue changed year-over-year?
- Veracyte's united states — total revenue increased by 17.3% year-over-year, from $105.88M to $124.15M.
- What is the long-term trend for Veracyte's united states — total revenue?
- Over 4 years (2021 to 2025), Veracyte's united states — total revenue has grown at a 25.4% compound annual growth rate (CAGR), from $200.98M to $496.6M.
- What does united states — total revenue mean?
- This metric represents the total gross income generated from the sale of diagnostic tests and services within the United States geographic market. It serves as a primary indicator of the company's commercial penetration and demand for its genomic testing portfolio in its domestic region. Tracking this figure helps investors assess the scale of operations and the effectiveness of the company's domestic sales and marketing strategies.